Anti-PD1/PD-L1 directed immune-checkpoint-inhibitors (ICI) are widely used to treat patients with advanced non-small cell lung cancer (NSCLC). The activity of ICI across NSCLC harboring oncogenic alterations is poorly characterized. The aim of our study was to address the efficacy of ICI in the context of oncogenic addiction.
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
Bironzo, P;Novello, S;
2019-01-01
Abstract
Anti-PD1/PD-L1 directed immune-checkpoint-inhibitors (ICI) are widely used to treat patients with advanced non-small cell lung cancer (NSCLC). The activity of ICI across NSCLC harboring oncogenic alterations is poorly characterized. The aim of our study was to address the efficacy of ICI in the context of oncogenic addiction.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
mdz167.pdf
Accesso aperto
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
2.17 MB
Formato
Adobe PDF
|
2.17 MB | Adobe PDF | Visualizza/Apri |
|
1-s2.0-S0923753419312840-main.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
515.73 kB
Formato
Adobe PDF
|
515.73 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
